BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/8/2022 12:06:55 PM | Browse: 819 | Download: 2034
 |
Received |
|
2021-07-25 16:35 |
|
Peer-Review Started |
|
2021-07-25 16:37 |
|
First Decision by Editorial Office Director |
|
2021-12-27 03:29 |
|
Return for Revision |
|
2021-12-27 03:29 |
|
Revised |
|
2022-01-15 09:20 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2022-02-24 06:13 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2022-02-27 19:56 |
|
Articles in Press |
|
2022-02-27 19:56 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-03-14 05:27 |
|
Publish the Manuscript Online |
|
2022-04-08 12:06 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Combination therapy (toripalimab and lenvatinib)-associated toxic epidermal necrolysis in a patient with metastatic liver cancer: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Kai-Kai Huang, Shan-Shan Han, Li-Ya He, Lin-Lin Yang, Bao-Ying Liang, Qing-Yu Zhen, Zi-Bo Zhu, Cai-Yun Zhang, Hong-Yi Li and Ying Lin |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Guangdong Provincial Key Laboratory of Chinese Medicine for Prevention and Treatment of Refractory Chronic Diseases |
2018B030322012 |
|
| Corresponding Author |
Ying Lin, MD, Chief Physician, Department of Dermatology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, No. 111 Dade Road, Yuexiu District, Guangzhou 510120, Guangdong Province, China. lin19791226@gzucm.edu.cn |
| Key Words |
Toxic epidermal necrolysis; Toripalimab; Lenvatinib; Programmed cell death-1 inhibitor; Liver cancer; Case report |
| Core Tip |
Both programmed cell death-1 (PD-1) inhibitors and lenvatinib, which exhibit a synergistic effect, are promising drugs for tumor treatment. However, we encountered a patient who presented with erythema, blisters and erosions on the face, neck, trunk and limbs 1 wk after combination therapy with lenvatinib and toripalimab, a PD-1 inhibitor. Skin biopsy was performed, and the diagnosis was confirmed as toxic epidermal necrolysis (TEN). We are the first group to report the occurrence of TEN, a grade 4 toxicity, after this combination therapy. Full-dose and long-term corticosteroids were administered, and the rashes gradually faded. |
| Publish Date |
2022-04-08 12:06 |
| Citation |
Huang KK, Han SS, He LY, Yang LL, Liang BY, Zhen QY, Zhu ZB, Zhang CY, Li HY, Lin Y. Combination therapy (toripalimab and lenvatinib)-associated toxic epidermal necrolysis in a patient with metastatic liver cancer: A case report. World J Clin Cases 2022; 10(11): 3478-3484
|
| URL |
https://www.wjgnet.com/2307-8960/full/v10/i11/3478.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v10.i11.3478 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
